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Rapid turnover of nonsense-containing mRNAs in Saccharomyces cerevisiae is dependent on Upf1p, Nmd2p,
and Upf3p, the products of the UPF1, NMD2/UPF2, and UPF3 genes, respectively. We showed previously that
Upf1p and Nmd2p interact and that this interaction is required for nonsense-mediated mRNA decay (F. He
and A. Jacobson, Genes Dev. 9:437–454, 1995; F. He, A. H. Brown, and A. Jacobson, RNA 2:153–170, 1996). In
this study we have used the yeast two-hybrid system to define other protein-protein interactions among the
essential components of this decay pathway. Nmd2p-Upf3p and Upf1p-Upf3p interactions were identified, and
the respective domains involved in these interactions were delineated by deletion analysis. The domains of
Upf1p and Upf3p putatively involved in their mutual interaction were found to correspond to the domains on
the two proteins which interact with Nmd2p, suggesting that Nmd2p bridges Upf1p and Upf3p. This conclusion
was reinforced by experiments showing that: (i) deletion of NMD2 completely abolishes interactions between
Upf1p and Upf3p and (ii) overexpression of full-length Nmd2p or Nmd2p fragments that retain Upf1p- and
Upf3p-interacting domains promotes 10- to 200-fold enhancement of Upf1p-Nmd2p-Upf3p complex formation.
These results; the observation that cells harboring either single or multiple deletions of UPF1, NMD2, and
UPF3 inhibit nonsense-mediated mRNA decay to the same extent; and an analysis of the possible targets of a
dominant-negative NMD2 allele indicate that Upf1p, Nmd2p, Upf3p, and at least one other factor are func-
tionally dependent, interacting components of the yeast nonsense-mediated mRNA decay pathway.
Decay of eukaryotic mRNAs can be triggered by poly(A)
shortening, endonucleolytic cleavage, or aberrant translation
(for a review, see reference 16). Aberrant translation includes
nonsense-mediated mRNA decay, the rapid turnover of an
otherwise stable mRNA that ensues when a ribosome encoun-
ters a premature translational termination codon. This phe-
nomenon has been observed in both prokaryotic and eukary-
otic cells but has been best characterized for Saccharomyces
cerevisiae (for reviews, see references 16 and 27). In the yeast
system this type of mRNA decay is cytoplasmic and depends
on, in addition to a nonsense codon, at least two cis-acting
coding-region sequences and several trans-acting factors (27).
The coding-region sequences include a site 39 to the nonsense
codon that appears to promote translational reinitiation and
messenger ribonucleoprotein (mRNP) conformational changes
and a sequence that, when translated, inactivates a ribosome’s
capacity to promote rapid mRNA decay (10a, 16, 25, 40).
trans-acting factors required for nonsense-mediated mRNA
decay were initially identified by a genetic screen for allosup-
pressors of the his4-38 frameshift allele (6). Subsequent
screens that also identified components of this pathway in-
cluded those seeking mutations that increased frameshifting
efficiencies (8, 20), suppressors of upstream initiation codons
(28), and omnipotent suppressors (41). Complementation of
these mutants, or the use of two-hybrid screens, led to the
isolation of the nonessential UPF1 (IFS2/SAL2/MOF4), NMD2
(UPF2/SUA1/IFS1), and UPF3 (SUA6) genes and to the dem-
onstration that mutations in these genes cause stabilization and
increased accumulation of nonsense-containing mRNAs while
having no effect on the stabilities or abundances of most wild-
type transcripts (5, 12, 13, 19–21, 25).
Of the trans-acting factors identified by these approaches,
that encoded by the UPF1 gene has been studied most exten-
sively. The UPF1 gene encodes a protein that has a predicted
molecular mass of 109 kDa, two putative Zn21 fingers near its
N terminus, and seven conserved motifs common to the mem-
bers of helicase superfamily I (1, 18, 22). Upf1p is localized
primarily in the cytoplasm and appears to be polyribosome
associated (3, 26). Upf1p has recently been purified from yeast
cells and shown to possess nucleic acid-binding activity as well
as nucleic acid-dependent ATPase and helicase activities (7).
Characterization of the NMD2 gene indicates that it encodes
an acidic protein with a predicted molecular mass of 127 kDa
and no significant homologies to other polypeptides (5, 12).
Two-hybrid analyses demonstrate that Nmd2p and Upf1p are
interacting proteins and that the Upf1p-interacting domain of
Nmd2p is localized within a 157-amino-acid segment at its C
terminus (14). Mutations in this domain that disrupt interac-
tion with Upf1p also inactivate nonsense-mediated mRNA de-
cay, indicating that Upf1p-Nmd2p interaction is required for
function of this decay pathway (14). The UPF3 gene encodes a
basic protein with a predicted molecular mass of 45 kDa (19).
Upf3p has no significant homologies to other proteins, but, like
Nmd2p (12), Upf3p contains multiple lysine-arginine-rich se-
quences that resemble bipartite nuclear localization sequences
known to target proteins to the nucleus (19).
Although the identification and initial characterization of
Upf1p, Nmd2p, and Upf3p have provided insight into the
mechanism of nonsense-mediated mRNA decay, the precise
functions and interactions of these factors are largely un-
known. Given that single disruptions of UPF1, NMD2, and
UPF3 inhibit nonsense-mediated mRNA decay to the same
extent, and that double disruptions are not additive, it appears
that Upf1p, Nmd2p, and Upf3p may function as a complex or
in closely related steps of this mRNA decay pathway (5, 12, 19,
37). Except for the interaction between Upf1p and Nmd2p (12,
* Corresponding author. Phone: (508) 856 2442. Fax: (508) 856
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14), interactions between these factors have not been charac-
terized extensively. To address this problem, we have used the
yeast two-hybrid system to identify genes encoding Nmd2p-
interacting proteins, to characterize the specific domains in-
volved in Upf1p-Nmd2p and Nmd2p-Upf3p interactions, and
to show that Nmd2p can interact with both Upf1p and Upf3p
simultaneously, possibly promoting the formation of a Upf1p-
Nmd2p-Upf3p complex in vivo. Our two-hybrid studies and the
analysis of mRNA decay in strains with one or more of these
factors deleted as well as in strains harboring a dominant-
negative NMD2 allele lead us to conclude that Upf1p, Nmd2p,
Upf3p, and at least one other factor are interacting compo-
nents of the nonsense-mediated mRNA decay pathway.
MATERIALS AND METHODS
General methods. Preparation of standard yeast media and methods of cell
culture were as described previously (30). Transformation of yeast was done by
the high-efficiency method (34), and DNA manipulations were performed by
standard techniques (32). All PCR amplifications were performed with TaqDNA
polymerase (38) and confirmed, when appropriate, by DNA sequencing accord-
ing to the method of Sanger et al. (33). Plasmid DNAs were prepared from
Escherichia coli DH5a.
Oligonucleotides. The oligonucleotides used in this study were obtained from
Operon, Inc., and are listed in Table 1.
Yeast strains. The yeast strains used in this study are listed in Table 2. The
two-hybrid tester strains containing deletions of UPF1, NMD2, and UPF3 were
constructed by gene replacement (31). HFY869, harboring a deletion of the
UPF1 gene, was constructed by transforming the L40 strain with a NotI-SalI
fragment from Bs-upf1::HIS3 (pHF1395) (Table 3). HFY863, harboring a dele-
tion of the NMD2 gene, was constructed by transforming the L40 strain with a
NotI-SalI fragment from Bs-nmd2::HIS3 (12). HFY866, harboring a deletion of
the UPF3 gene, was constructed by transforming the L40 strain with a NotI-SalI
fragment from Bs-upf3::HIS3 (pHF1409) (Table 3). In each case, His1 transfor-
mants were selected, the disruption event was confirmed by PCR analysis, and
the inactivation of nonsense-mediated mRNA decay was monitored by Northern
blot analysis with CYH2 as a probe. The yeast strains HFY870 and HFY861,
harboring deletions of the UPF1 and UPF3 genes, respectively, were constructed
in the same way as the HFY869 and HF866 strains except that strain HFY1200
was used for transformations. HFY872, harboring deletions of both the UPF1
and UPF3 genes, was constructed by transforming HFY861 with a NotI-SalI
fragment from Bs-upf1-1::URA3 (pHF1397) (Table 3). HFY874, harboring de-
letions of both the NMD2 and UPF3 genes, was constructed by transforming
HFY861 with a NotI-SalI fragment from Bs-nmd2::URA3 (pHF275) (Table 3).
HFY883, harboring a triple deletion of the UPF1, NMD2, and UPF3 genes, was
constructed by transforming HFY874 with a BamHI-XhoI fragment from
pRS314-upf1::LEU2 (see below). For each construction, the disruption event was
confirmed by PCR analysis.
Plasmid constructions. The plasmids used in this study included (i) the GAL4
activation domain [GAL4(AD)]-containing plasmids pACTII (a generous gift
from Stephen Elledge, University of Texas, Houston), pGAD-C1, pGAD-C2,
and pGAD-C3 and plasmid libraries containing yeast genomic DNA fused to the
GAL4(AD) (generous gifts from Philip James and Elizabeth Craig, University of
Wisconsin Medical School, Madison, and David Mangus, University of Massa-
chusetts Medical School, Worcester); (ii) the GAL4 and lexA DNA-binding
domain [GAL4(DB) and lexA(DB)]-containing plasmids pMA424 and pBTM116
(generous gifts from Stanley Fields, University of Washington, Seattle, and
Stanley Hollenberg, Fred Hutchinson Cancer Research Center, Seattle, respec-
tively); (iii) pRS314-upf1::LEU2, a UPF1 deletion-disruption plasmid (a gener-
ous gift from Aidan Hennigan); (iv) pRS313, pRS314, and pRS316, yeast shuttle
plasmids containing ARS4 and CEN6 and the HIS3 gene (pRS313), the TRP1
gene (pRS314), or the URA3 gene (pRS316) gene (35); (v) YEplac112, a yeast
2mm vector containing the TRP1 gene (11); (vi) Bluescript KS(1), an E. coli
cloning vector (Stratagene); (vii) Bs-nmd2::HIS3, pRS315-NMD2(X-S), pRS315-
HA-NMD2(X-S), pRS316-HA-NMD2(X-S), pRS315-HA-nmd2-CD166, YE-
plac112-NMD2(X-S), YEplac112-HA-NMD2(X-S), pHF926, pACTII-NMD2-
CD166, and pACTII-NMD2DN, the construction of which was described
previously (12, 14); and (viii) the set of plasmids whose features are summarized
in Tables 3 and 4 and whose construction is outlined below.
(i) GAL4(AD)-UPF1 fusion constructs. All GAL4(AD)-UPF1 fusions used for
mapping the Nmd2p- and Upf3p-interacting domains of Upf1p were constructed
by using PCR-derived fragments. In each case, a pair of oligonucleotide primers
containing either an EcoRI site (59 primer) or a SalI site (39 primer) was used for
amplification (Table 1). The PCR-amplified fragment was digested with EcoRI
and SalI and ligated into pACTII* digested previously with EcoRI and XhoI. The
resulting plasmids each carried a distinct fragment from the UPF1 coding region
(Table 4). The plasmid pACTII* is a modified version of pACTII (9) and was
constructed by ligating an EcoRI linker (GGAATTCC) into pACTII digested
previously with SmaI. This led to a change from GCC CCG GGG to GCC CCG
GAA TCC GGG, in which the EcoRI site is in the same reading frame as that
of pMA424, pBTM116, and pGAD-C1, pGAD-C2, and pGAD-C3.
(ii) lexA(DB)-NMD2 fusion constructs. The plasmid pHF1186 (Table 4) was
used for the two-hybrid screen. It carries a lexA(DB)-NMD2DN(326–1089) fusion
and was constructed as follows. A 210-bp PCR-derived EcoRI-ClaI fragment
(from codon 326 to the ClaI site in the NMD2 coding region) was ligated into
Bluescript KS(1) digested previously with EcoRI and ClaI. The resulting plas-
mid, pHF1201 (Table 3), was then digested with ClaI and SalI and ligated to a
3.5-kb ClaI-SalI NMD2 fragment isolated from pRS316-HA-NMD2(X-S) (14),
creating pHF1203. A 59-end 1,339-bp EcoRI-PstI fragment and a 39-end 2.4-kb
PstI-SalI fragment were individually isolated from pHF1203 and were ligated
into pBTM116 digested previously with EcoRI and SalI in a three-fragment
ligation reaction.
The plasmid pHF1268, which carries a lexA(DB)-NMD2 fusion containing an
N-terminal deletion up to residue 772, was constructed by ligating a 2.3-kb
EcoRI-SalI fragment isolated from pHF1186 into pBTM116 digested previously
with EcoRI and SalI. The plasmids pHF1308, pHF1309, pHF1311, and
pHF1313, which carry lexA(DB)-NMD2 fusions containing N-terminal deletions
up to residues 473, 564, 638, and 693, respectively, were constructed by using
pHF1268. In each case, a pair of oligonucleotide primers containing either
EcoRI/BamHI sites (59 primer) or an EcoRI site (39 primer, NMD2-M11) were
used for amplification (Table 1) (14). The PCR-amplified fragment was digested
with EcoRI and ligated into pHF1268 digested previously with EcoRI. The
correct orientation of each insert was confirmed by restriction digestion. The
plasmids pHF1304 and pHF1306, which carry lexA(DB)-NMD2 fusions contain-
ing N-terminal deletions up to residues 817 and 879, respectively, were con-
structed by using PCR-derived fragments. The oligonucleotide primer pairs
NMD2-TH29/NMD2-M10 and NMD2-TH30/NMD2-M10 were used for amplifi-
cation (Table 1) (14). The PCR-amplified fragments were digested with EcoRI
and SalI and ligated individually into pBTM116 digested previously with EcoRI
and SalI. Plasmid pHF1270, which carries a lexA(DB)-NMD2 fusion containing
an N-terminal deletion up to residue 933, was constructed by ligating the 1.1-kb
EcoRI-SalI fragment isolated from pHF1050 (see below) into pBTM116 di-
gested previously with EcoRI and SalI.
The plasmids pHF1262, pHF1264, pHF1266, pHF1352, pHF1349, pHF1348,
pHF1345, and pHF1344 carry lexA(DB)-NMD2 fusions with distinct C-terminal
deletions and were constructed by using pHF1186. In each case, a ClaI-SalI
fragment from the C-terminal region of the individual HA-nmd2 alleles that
harbor distinct C-terminal deletions (see below and Table 3) was isolated and
ligated into pHF1186 digested previously with ClaI and SalI. The plasmids
pHF1467, pHF1469, pHF1471, and pHF1473 carry lexA(DB)-NMD2(564–923),
lexA(DB)-NMD2(564–883), lexA(DB)-NMD2(564–816), and lexA(DB)-NMD2
(564–803) fusions, respectively. They were constructed by ligating a 630-bp
EcoRI-EcoRI fragment (from codon 564 to the EcoRI site in the coding region
of pHF1309-borne NMD2) into pHF1262, pHF1264, pHF1266, and pHF1352
digested previously with EcoRI. The plasmids pHF1528 and pHF1530, which
carry lexA(DB)-NMD2(564–771) and lexA(DB)-NMD2(564–692) fusions, respec-
tively, were constructed by the following three-fragment ligations: a PCR-ampli-
fied EcoRI-BglII fragment and a 0.6-kb BglII-SalI fragment isolated from
pHF926 were ligated into pBTM116 digested previously with EcoRI and SalI.
The oligonucleotide pairs NMD2-TH25/NMD2-TH31 and NMD2-TH25/NMD2-
TH32 (Table 1) were used for amplification of the respective fragments.
(iii) GAL4(DB)-NMD2 and GAL4(AD)-NMD2 fusion constructs. The plasmid
pHF1050, which carries the GAL4(DB)-NMD2(933–1089) fusion, was used for
mapping the Nmd2p-interacting domain of Upf1p. It was constructed by ligating
a PCR-amplified EcoRI-SalI fragment into pMA424 digested previously with
EcoRI and SalI. The oligonucleotides NMD2-TH18 and NMD2-M10 were used
for PCR amplification (Table 1) (14).
The plasmids pHF1415, pHF1417, pHF1419, pHF1421, pHF1425, and
pHF1427, which carry GAL4(AD)-NMD2 fusions containing N-terminal dele-
tions up to residues 473, 564, 638, 693, 817, and 879, respectively, and the
plasmids pHF1670, pHF1672, pHF1674, pHF1676, pHF1534, and pHF1536,
which carry GAL4(AD)-NMD2 fusions each containing an internal fragment
beginning at codon 564, were constructed in the same way. In each case, a
BamHI-SalI fragment was isolated from the corresponding lexA(DB)-NMD2
fusion plasmid (Table 4) and ligated into pGAD-C1 digested previously with
BamHI and SalI. The plasmid pHF1423, which carries the GAL4(AD)-
NMD2(772–1089) fusion, was constructed by ligating a PCR-amplified BamHI-
SalI fragment into pGAD-C1 digested previously with BamHI and SalI. The
oligonucleotides NMD2-TH28 and NMD2-M10 were used for PCR amplifica-
tion. The plasmids pHF1429 and pHF1431, which carry the GAL4(AD)-
NMD2(933–1089) and GAL4(AD)-NMD2(326–563) fusions, respectively, were
constructed by ligating EcoRI-SalI fragments isolated from pHF1050 and
pHF1344, respectively, into pGAD-C1 digested previously with EcoRI and SalI.
The plasmid pHF1441, which carries a GAL4(AD)-NMD2 fusion with the orig-
inal dominant-negative fragment encoding Nmd2p residues 326 to 1089 (12), and
the plasmids pHF1458, pHF1456, pHF1454, pHF1452, pHF1450, pHF1448, and
pHF1446, which carry GAL4(AD)-NMD2 fusions each containing a distinct
C-terminal deletion, were constructed by using pHF1431. In each case, a ClaI-
SalI fragment from the C-terminal regions of the individual HA-nmd2 alleles,
each harboring a distinct C-terminal deletion (Table 3), was isolated and ligated
into pHF1431 digested previously with ClaI and SalI.
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(iv) lexA(DB)-UPF3 and GAL4(AD)-UPF3 fusion constructs. All lexA(DB)-
UPF3 fusions used for mapping the Nmd2p- and Upf1p-interacting domains of
Upf3p were constructed by using PCR-derived fragments. In each case, a pair of
oligonucleotide primers containing either a BamHI site (59 primer) or a SalI site
(39 primer) were used for amplification (Table 1). The PCR-amplified fragment
was digested with BamHI and SalI and ligated into pBTM116 digested previously
with BamHI and SalI. The resulting plasmids each carried a distinct fragment
from the UPF3 coding region (Table 4). All GAL4(AD)-UPF3 fusions were
constructed in the same way as the lexA(DB)-UPF3 fusions, except that each
PCR-derived BamHI-SalI fragment was ligated into pGAD-C2 digested previ-
ously with BamHI and SalI. The plasmid pHF1686, isolated from a two-hybrid
screen by using lexA(DB)-NMD2DN(326–1089) as bait, carries a GAL4(AD)-
UPF3 fusion including 0.7 kb of UPF3 C-terminal coding sequences (from codon
152 to the translational stop codon) and 1.3 kb distal to the UPF3 stop codon.
(v) GAL4(AD)-DNLS-NMD2 fusion constructs. GAL4(AD)-DNLS-NMD2 fu-
sions each containing an N-terminal deletion of Nmd2p, and the GAL4(AD)-
DNLS-NMD2 fusions each containing Nmd2p internal fragments beginning at
codon 564, were constructed in the same way. In each case, a BamHI-SalI NMD2
fragment isolated from the corresponding lexA(DB)-NMD2 fusion plasmid was
ligated into pACTII-DNLS digested previously with BamHI-SalI. The plasmid
pACTII-DNLS was constructed by a three-fragment ligation, as follows. A 0.4-kb
HindIII-BamHI fragment [containing the GAL4(AD)-DNLS] PCR amplified
from pACTII-NMD2DN (14) and a 1.1-kb BamHI-SalI fragment (containing the
ADH1 terminator) isolated from pACTII were ligated into pACTII digested
TABLE 1. Oligonucleotides
Name Sequence (59 to 39)
UPF1-TH1..............................................................CCGGAATTCATGGTCGGTTCCGGTTCT
UPF1-TH2..............................................................CCGGAATTCTGTGCGTATTGTGGTATAGATTCT
UPF1-TH3..............................................................CCGGAATTCGATACCGTTTTGGAATGTTATAAC
UPF1-TH4..............................................................CCGGAATTCGAGTTGAAAGTTGCCATCGGTGAT
UPF1-TH3-2 ..........................................................ACGCGTCGACTTATATTCCCAAATTGCTGAAGTC
UPF1-TH6..............................................................ACGCGTCGACTTAGGATCTCCATTTTGCCTCCAACTT
UPF1-TH7..............................................................ACGCGTCGACTTAGTTAGATTCGAAAGTAGATAAAGT
UPF1-TH10............................................................CCGGAATTCGGTGCTGGTGATAAGCGCTTA
UPF1-TH13............................................................CGCGTCGACTTATACATGACTAACAGCGTTCGA
UPF1-TH14............................................................CGCGTCGACTTAAACACATGTGCAACATACGAC
UPF1-TH15............................................................CGCGTCGACTTAACGCTGTTCAATCGTTACACC
UPF1-TH16............................................................CGCGTCGACTTATTGCTCTGCGACCCATGATAA
UPF1-TH17............................................................CGCGTCGACTTAGGCACAAGGTATTCTACAAAG
UPF1-DS1 ..............................................................ACAGAATTCATGAACGGGAAATAAGAA
UPF1-DS2 ..............................................................CGAAGATCTTTGATAATGACAATGATTGATGTA
UPF1-DS3 ..............................................................CGAAGATCTATCGATTTCGGTGAACCCTGTTAAAATAAA
UPF1-DS4 ..............................................................CGCGTCGACTATTATCTGTGGTATCATTTTCTA
NMD2-TH18..........................................................CCGGAATTCAGCGACTCTGATTTGGAGTATGGT
NMD2-TH21..........................................................CCGGAATTCATCACGAATCAGATATTGCCACCC
NMD2-TH22..........................................................CGCAGATCTCAACTTTTTATTGCGTTTAATGAT
NMD2-TH23..........................................................CGCAGATCTCATTGCTTTGCCTGATGTTTTCCT
NMD2-TH24..........................................................ACAGAATTCGGATCCAGTGAAATGATTAAATTTCAA
NMD2-TH25..........................................................ACAGAATTCGGATCCAAATCATTAAATGTTACGGTA
NMD2-TH26..........................................................ACAGAATTCGGATCCGGTCTATACAGTTACCGCCGC
NMD2-TH27..........................................................ACAGAATTCGGATCCGTTTTGTTAGATACTATCTAC
NMD2-TH28..........................................................CGCGGATCCGAATTCAGAGTTTCAAGCACATTT
NMD2-TH29..........................................................ACAGAATTCGGATCCAAAGACGACAGAGTGAAGGGA
NMD2-TH30..........................................................ACAGAATTCGGATCCCATCAGGCAAAGCAAGACGAA
NMD2-TH31..........................................................ACGCAGATCTCATGTTTCCTTGGGTAAAGGTTG
NMD2-TH32..........................................................ACGCAGATCTCAATCGGATTTTATCATTTCAAA
NMD2-TH33..........................................................ACGCAGATCTCAGCCTAGAACTTTTGTTAATAA
NMD2-TH34..........................................................ACGCAGATCTCAGAAGAAGATGATGTTTTTAAC
UPF3-HT1..............................................................ACGCGGATCCAAATGAGCAATGTGGCTGGGGAATTG
UPF3-HT2..............................................................ACGCGGATCCAAGACAACTTATCAGACTTGGAAAAA
UPF3-HT3..............................................................ACGCGGATCCAAAATGAAGAAGACGAAATTTTTAAA
UPF3-HT4..............................................................ACGCGGATCCAAAATAAAAACGCCAAAAAGAAATTC
UPF3-HT5..............................................................CGCGTCGACCTACTTCTTGGTATCATCACGATG
UPF3-HT6..............................................................CGCGTCGACCTATTTCTTCTTTTTGTTCTTATTCTT
UPF3-HT7..............................................................CGCGTCGACCTATGTTCCTACTAGCGCGGCATCCTT
UPF3-HT8..............................................................CGCGTCGACCTAGAACAAGAAATTGCACCGAGAATA
UPF3-HT9..............................................................ACGCGGATCCAAAATGAGACGGTAGATCCTAAAAAG
UPF3-HT10............................................................ACGCGGATCCAAGGTAAATCAACCGAGAATGAAGGA
UPF3-1 ...................................................................TGCTCTAGATACTTGATAGGATTTTATTGCCGT
UPF3-2 ...................................................................CCGCTCGAGATGAGCAATGTGGCTGGGGAATTG
UPF3-3 ...................................................................GATGTTTGAGTGAATTTCTTTACG
UPF3-8 ...................................................................CGAAGATCTGATAGATTACTATATATTTCAGCA
UPF3-9 ...................................................................CGAAGATCTTAAAAGCTCATGGCTTCTTATATA
UPF3-10 .................................................................CGCGTCGACTCAGTTAAGATAGCATTCATTTGT
UPF3-11 .................................................................GTAATCCATGGTAGATTACTATATATTTCAGCAGAA
UPF3-12 .................................................................CGTAAGATGGCAAAAAATTCATCTGCA
UPF3-FLAG ..........................................................TCTACCATGGATTACAAGGACGACGATGACAAGATGAGCAATGTGGCTGGGAATTG
GAL4(AD)-HIII ...................................................CGCAAGCTTTGCAAAGATGGATAA
GAL4(AD)-BamHI ..............................................CGCGGATCCCTCTTTTTTTGGGTTTGGTGGGGT
ADH1p-XbaI.........................................................GATCTCTAGAGCTTGCATGCAACTTCTTTTCTT
ADH1p-NcoI.........................................................GACTCCATGGTTGCAAAGCTTGGAGTTGATTGT
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previously with HindIII and SalI. This led to a replacement of the GAL4(AD) by
the GAL4(AD)-DNLS and a change of reading frame at the BamHI site from
XGGATC CGA to GGA TCCGXX. The latter BamHI site is in the same frame
as that of pGAD-C1. The oligonucleotide primers GAL4(AD)-HIII and
GAL4(AD)-BamHI were used for PCR amplification (Table 1). AllGAL4(AD)-
DNLS-NMD2 fusions containing C-terminal deletions of Nmd2p were con-
structed by three-fragment ligations. In each case, a 0.7-kb HindIII-ClaI frag-
ment isolated from the original dominant-negative fragment of NMD2
[containing the GAL4(AD) and a portion of NMD2)] and a ClaI-SalI fragment
isolated from the C-terminal regions of the individual HA-nmd2 alleles harbor-
ing distinct C-terminal deletions (Table 3) were ligated into pACTII previously
digested with HindIII and SalI. Transcription of all of these gene fusions was
driven by the potent ADH1 promoter.
(vi) Construction of upf1::HIS3, upf1-1::URA3, nmd2::URA3, and upf3::HIS3
alleles. The plasmids pHF1395 and pHF1397, which carry the upf1::HIS3 and
upf1-1::URA3 alleles, respectively, were constructed in two steps. First, a 401-bp
PCR-derived EcoRI-BglII fragment containing the promoter and 59 untranslated
region (59-UTR) of UPF1 and a 449-bp PCR-derived BglII-SalI fragment con-
taining sequences 39 to the translational stop codon of UPF1 were ligated into
Bluescript digested previously with EcoRI and SalI. The oligonucleotide pairs
UPF1-DS1/UPF1-DS2 and UPF1-DS3/UPF1-DS4 were used for PCR amplifica-
tion of the two fragments, respectively, and this three-fragment ligation reaction
generated pHF1390. Second, a 1.8-kb BamHI-BamHI HIS3 fragment or a 1.2-kb
BamHI-ClaI URA3 fragment was ligated into pHF1390 digested previously with
BglII or BglII and ClaI, respectively. This led to a replacement of the entire UPF1
coding region by either the HIS3 or URA3 gene. The plasmid pHF275, which
carries the nmd2::URA3 allele, was also constructed in two steps. First, a 1.1-kb
XbaI-BamHI fragment containing the promoter, the 59-UTR, and a portion of
the N-terminal coding sequences of NMD2 was isolated from pRS315-
NMD2(X-S) (14) and ligated into Bluescript digested previously with XbaI and
BamHI, generating Bs-NMD2(X-B). Second, a 1.2-kb BamHI-ClaI URA3 frag-
ment and a 1.1-kb ClaI-EcoRI fragment from the NMD2 coding region were
ligated into Bs-NMD2(X-B) digested previously with BamHI and EcoRI. This
led to a replacement of the NMD2 coding region from the BamHI site to the ClaI
site by the URA3 gene. Plasmid pHF1409, carrying the upf3::HIS3 allele, was
constructed in the same way as pHF1395 except that a 433-bp PCR-derived
XbaI-BglII fragment (containing the promoter and 59-UTR of UPF3) and a
381-bp PCR-derived BglII-SalI fragment (containing sequences 39 to the trans-
lational stop codon of UPF3) were ligated into Bluescript digested previously
with XbaI and SalI in a three-fragment ligation reaction, generating pHF1286.
The oligonucleotide pairs UPF3-1/UPF3-8 and UPF3-9/UPF3-10 were used for
PCR amplification of the respective fragments.
(vii) NMD2-containing plasmids. The plasmids pHF1207 and pHF1206, which
carry HA-nmd2 alleles encoding C-terminal Nmd2p deletions of 206 and 273
residues, respectively, were constructed by using pHF926 (14). In either case, a
PCR-derived EcoRI-BglII fragment was ligated into pHF926 digested previously
with EcoRI and BglII. This led to a replacement of the wild-type NMD2 fragment
(from the EcoRI site in the coding region to the translation stop codon) by a
C-terminally truncated one. The oligonucleotide pairs NMD2-M11/NMD2-TH23
and NMD2-M11/NMD2-TH22 were used for PCR amplification of the respective
fragments. The plasmids pHF1342, pHF1301, pHF1338, pHF1298, and
pHF1296, which carry HA-nmd2 alleles containing C-terminal deletions of 286,
318, 397, 452, and 526 codons, respectively, were constructed in the same way as
pHF1207 and pHF1206. In each case, a PCR-derived ClaI-BglII fragment was
ligated into pHF926 digested previously with ClaI and BglII. This led to a
replacement of the wild-type NMD2 fragment (from the ClaI site in the coding
region to the translation stop codon) by a C-terminally truncated one. The
oligonucleotide pairs hf219-1/NMD2-TH5, hf219-1/NMD2-TH31, hf219-1/NMD2-
TH32, hf219-1/NMD2-TH33, and hf219-1/NMD2-TH34 were used for amplifica-
tion (Table 1) (14). The plasmid pHF1569, which carries the HA-nmd2(564–
1089) allele, was constructed in two steps. First, the XbaI-SalI fragment
containing the HA-nmd2-ND771 allele was isolated from pHF692 (14) and
ligated into pRS316, generating pHF1520. Second, an EcoRI-EcoRI fragment
containing NMD2 sequences from codon 564 to the EcoRI site in the coding
region was isolated from pHF1309 and ligated into pHF1520 digested previously
by EcoRI. The plasmid pHF1085, which carries an ADH1 promoter-driven HA-
NMD2 allele, was constructed by ligating a 431-bp PCR-amplified XbaI-NcoI
fragment, containing the promoter and 59-UTR of the ADH1 gene, into YE-
plac112-HA-NMD2(X-S) (12) digested previously with XbaI and NcoI. This led
TABLE 2. Yeast strains
Strain Genotype Source (reference)
GGY1::171 his3 leu2 URA3::GAL1-lacZ gal4D gal80D Stanley Fields
L40 MATa ade2 his3D200 leu2-3,112 trp1-901 LYS2::(lexAop)4-HIS3 URA3::(lexAop)8lacZ gal4 gal80 Stanley Hollenberg
HFY869 Same as L40 but containing upf1::HIS3 This study
HFY863 Same as L40 but containing nmd2::HIS3 This study
HFY866 Same as L40 but containing upf3::HIS3 This study
HFY1200 MATa ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100 UPF1 NMD2 UPF3 He and Jacobson (12)
HFY870 MATa ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100 upf1::HIS3 NMD2 UPF3 This study
HFY1300 MATa ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100 UPF1 nmd2::HIS3 UPF3 He and Jacobson (12)
HFY861 MATa ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100 UPF1 NMD2 upf3::HIS3 This study
HFY3000 MATa ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100 upf1::URA3 nmd2::HIS3 UPF3 He and Jacobson (12)
HFY872 MATa ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100 upf1-1::URA3 NMD2 upf3::HIS3 This study
HFY874 MATa ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100 UPF1 nmd2::URA3 upf3::HIS3 This study
HFY883 MATa ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100 upf1::LEU2 nmd2::URA3 upf3::HIS3 This study
TABLE 3. Plasmids containing UPF1, NMD2, and UPF3 alleles
Plasmid Vector and UPF1, NMD2, and UPF3 allelea
pHF1390 .............Bs-upf1DCDS (EcoRI-BglII/BglII-ClaI-SalI)
pHF1395 .............Bs-upf1::HIS3
pHF1397 .............Bs-upf1-1::URA3
pHF275 ...............Bs-nmd2::URA3
pHF1201 .............Bs-NMD2(326–391)(E-C)
pHF1203 .............Bs-NMD2DN(326–1089)(E-S)
pHF1628 .............pRS313-ADH1p-HA-NMD2(X-S)
pHF1629 .............pRS313-ADH1p-HA-nmd2-CD166 (deletion of 166
aa from the C terminus)
pHF1630 .............pRS313-ADH1p-HA-nmd2-CD526 (deletion of 526
aa from the C terminus)
pHF1648 .............pRS313-ADH1p-HA-nmd2(564–1089) (encoding
residues 564 to 1089)
pHF1520 .............pRS316-HA-nmd2-ND771 (deletion of 771 aa from
the N terminus)
pHF1207 .............pRS316-HA-nmd2-CD206 (deletion of 206 aa from
the C terminus
pHF1342 .............pRS316-HA-nmd2-CD286 (deletion of 286 aa from
the C terminus)
pHF1301 .............pRS316-HA-nmd2-CD318 (deletion of 318 aa from
the C terminus)
pHF1338 .............pRS316-HA-nmd2-cD397 (deletion of 397 aa from
the C terminus)
pHF1298 .............pRS316-HA-nmd2-CD452 (deletion of 452 aa from
the C terminus)
pHF1296 .............pRS316-HA-nmd2-CD526 (deletion of 526 aa from
the C terminus)
pHF1569 .............pRS316-ADH1p-HA-nmd2(564–1089) (encoding
residues 564 to 1089)
pHF1085 .............YEplac112-ADH1p-HA-NMD2(X-S)
pHF1286 .............Bs-upf3DCDS (XbaI-BglII/BglII-SalI)
pHF1409 .............Bs-upf3::HIS3
pHF1288 .............pRS314-UPF3(B-S)
pHF1292 .............pRS316-UPF3(X-S)
pHF1385 .............pRS316-FLAG-UPF3(X-S)
pHF1427 .............YEplac112-UPF3(X-S)
pHF1403 .............YEplac112-ADH1p-FLAG-UPF3(X-S)
pHF1463 .............YEplac112-ADH1p-HA-UPF3(X-S)
a aa, amino acids.
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to a replacement of the NMD2 promoter region by that of ADH1. The oligonu-
cleotides ADH1p-XbaI and ADH1p-NcoI (Table 1) were used for PCR ampli-
fication. The plasmids pHF1628, pHF1629, pHF1630, and pHF1648, which carry
the ADH1 promoter-driven HA-NMD2, HA-nmd2-CD166, HA-nmd2-CD526,
and HA-nmd2(564–1089) alleles, respectively, were constructed by three-frag-
ment ligations. In each case, a 431-bp XbaI-NcoI fragment (containing the ADH1
promoter region) isolated from pHF1085 and an NcoI-SalI fragment (containing
the respective NMD2 alleles) isolated from pHF1085, pHF707 (14), pHF1296,
and pHF1569, were ligated into pRS313 digested previously with XbaI and SalI.
(viii) UPF3-containing plasmids. Plasmid pHF1427, which carries a wild-type
UPF3 gene, was constructed by a three-fragment ligation. A PCR-derived XbaI-
SnaBI fragment (containing 427 bp of the promoter region and 559 bp of the
N-terminal portion of the UPF3 coding region) and a 2.0-kb SnaBI-SalI fragment
(containing sequences including the C-terminal portion of the UPF3 coding
region and the 39-UTR region), isolated from pHF1686, were ligated into YE-
plac112 digested previously with XbaI and SalI. The oligonucleotide primers
UPF3-1 and UPF3-3 were used in PCR amplification. Plasmids pHF1288 and
pHF1292 both carry the wild-type UPF3 gene and were constructed by ligating
either a BamHI-SalI or an XbaI-SalI fragment isolated from pHF1427 into
pRS314 or pRS316 digested previously with either BamHI and SalI or XbaI and
SalI, respectively. The plasmid pHF1385, which carries a FLAG-UPF3 allele, was
constructed by using pHF1292. A PCR-derived XbaI-NcoI fragment (containing
the UPF3 promoter region) and a PCR-derived NcoI-HindIII fragment (contain-
ing the FLAG epitope and an N-terminal portion of the UPF3 coding region)
TABLE 4. lexA(DB), GAL4(DB), and GAL4(AD) fusion constructs
Plasmid Vector and relevant sequence Plasmid Vector and relevant sequence
pHF1668. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-UPF1(1–971) pHF1672. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(564–883)
pHF1163. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(1–666) pHF1674. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(564–816)
pHF1161. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(1–555) pHF1676. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(564–803)
pHF1159. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(1–420) pHF1534. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(565–771)
pHF1011. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(1–289) pHF1536. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(564–692)
pHF1017. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(1–207) pHF1355. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(473–1089)
pHF1177. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(1–181) pHF1357. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(564–1089)
pHF1175. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(1–153) pHF1359. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(638–1089)
pHF1013. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(62–289) pHF1361. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(693–1089)
pHF1019. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(62–207) pHF1363. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(772–1089)
pHF1181. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(62–181) pHF1365. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(817–1089)
PHF1015 . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(80–289) pHF1367. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(879–1089)
pHF1165. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(290–971) pHF1258. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-DNLS-NMD2(326–883)
pHF1169. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII*-UPF1(556–971) pHF1256. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-DNLS-NMD2(326–816)
pHF1050. . . . . . . . . . . . . . . . . . . . . . . . . . pMA424-NMD2(933–1089) pHF1377. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-DNLS-NMD2(326–803)
pHF1186. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2DN(326–1089) pHF1375. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-DNLS-NMD2(326–771)
pHF1308. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(473–1089) pHF1373. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-DNLS-NMD2(326–692)
pHF1309. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(564–1089) pHF1371. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-DNLS-NMD2(326–637)
pHF1311. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM115-NMD2(638–1089) pHF1369. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-DNLS-NMD2(326–563)
pHF1313. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(693–1089) pHF1493. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(564–923)
pHF1268. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(772–1089) pHF1495. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(564–883)
pHF1304. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(817–1089) pHF1497. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(564–816)
pHF1306. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(879–1089) pHF1499. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(564–803)
pHF1270. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(933–1089) pHF1540. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(564–771)
pHF1262. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(326–923) pHF1542. . . . . . . . . . . . . . . . . . . . . . . . . . pACTII-C1-DNLS-NMD2(564–692)
pHF1264. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(326–883) pHF1412. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(1–387)
pHF1266. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(326–816) pHF1650. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(32–387)
pHF1352. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(326–803) pHF1656. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(78–387)
pHF1349. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(326–771) pHF1318. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(152–387)
pHF1348. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(326–692) pHF1320. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(205–-387)
pHF1345. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(326–637) pHF1322. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(279–387)
pHF1344. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(326–563) pHF1332. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(1–278)
pHF1467. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(564–923) pHF1330. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(1–204)
pHF1469. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(564–883) pHF1316. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(1–151)
pHF1471. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(564–816) pHF1652. . . . . . . . . . . . . . . . . . . . . . . . . . pMTB116-UPF3(32–278)
pHF1473. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(564–803) pHF1658. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(78–278)
pHF1528. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(564–771) pHF1324. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(152–278)
pHF1530. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-NMD2(564–692) pHF1654. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(32–204)
pHF1441. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2DN(326–1089) pHF1660. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(78–204)
pHF1415. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(473–1089) pHF1326. . . . . . . . . . . . . . . . . . . . . . . . . . pBTM116-UPF3(152–204)
pHF1417. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(564–1089) pHF1414. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(1–387)
pHF1419. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(638–1089) pHF1636. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(32–387)
pHF1421. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(693–1089) pHF1642. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(78–387)
pHF1423. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(772–1089) pHF1274. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(152–387)
pHF1425. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(817–1089) pHF1276. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(205–387)
pHF1427. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(879–1089) pHF1278. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(279–387)
pHF1429. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(933–1089) pHF1336. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(1–278)
pHF1458. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(326–923) pHF1334. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(1–204)
pHF1456. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(326–883) pHF1272. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(1–151)
pHF1454. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(326–816) pHF1638. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(32–278)
pHF1452. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(326–803) pHF1644. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(78–278)
pHF1450. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(326–771) pHF1280. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(152–278)
pHF1448. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(326–692) pHF1640. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(32–204)
pHF1446. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(326–637) pHF1646. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(78–204)
pHF1431. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(326–563) pHF1282. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C2-UPF3(152–204)
pHF1670. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-NMD2(564–923) pHF1686. . . . . . . . . . . . . . . . . . . . . . . . . . pGAD-C1-UPF3(152–387)
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were ligated into pHF1292 digested previously with XbaI and HindIII. The
oligonucleotide pairs UPF3-1/UPF3-11 and UPF3-FLAG/UPF3-12 were used for
amplification of the respective fragments. The plasmid pHF1403, which carries
an ADH1 promoter-driven FLAG-UPF3 allele, was constructed by ligating an
NcoI-SalI fragment (containing the FLAG-UPF3 allele), isolated from pHF1385,
into pHF1085 digested previously with NcoI and SalI. Plasmid pHF1463, which
carries an ADH1 promoter-driven HA-UPF3 allele, was constructed by ligating a
PCR-derived XhoI-SalI fragment (containing the entire UPF3 coding region and
approximately 0.4 kb from its 39-UTR) into pHF1085 digested previously with
XhoI and SalI. The oligonucleotide primers UPF3-2 and UPF3-10 were used for
PCR amplification.
Two-hybrid screening. The yeast strain L40 was cotransformed with both
pHF1186 [carrying the lexA(DB)-NMD2DN(326–1089) fusion] and one of the
libraries containing genomic DNA fragments fused to the GAL4(AD). Trans-
formants were grown for 10 h in synthetic liquid medium lacking tryptophan and
leucine to maintain selection for the lexA-NMD2DN(326–1089) fusion plasmid
and the library plasmid, respectively. The transformants were then plated on
synthetic medium lacking histidine, tryptophan, and leucine and containing 5
mM 3-aminotriazole. After 4 to 6 days of growth on plates at 308C, His1
transformants were replica plated to X-Gal (5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside) plates and were incubated until blue colonies appeared. Li-
brary plasmids were recovered from blue colonies as previously described (12).
To test for specificity, isolated library plasmids were individually retransformed
into the original L40 strain with either (i) the lexA(DB)-NMD2DN fusion, (ii) a
series of the lexA(DB)-NMD2DN fusions containing deletions from the C termi-
nus, or (iii) the lexA(DB) vector only. The plasmids encoding Nmd2DNp-inter-
acting proteins were characterized further by sequence analysis. DNA sequences
were compared to existing sequence databases by using the BlastN program (2).
Two-hybrid interaction assay. The two-hybrid tester strain GGY1::171 was
used to assay interactions between Upf1p and Nmd2p. The two-hybrid tester
strain L40 was used to assay interactions between Nmd2p and Upf3p and be-
tween Upf1p and Upf3p. In each case, a GAL4(DB) or lexA(DB) fusion con-
struct (Table 4) was cotransformed with a GAL4(AD) construct into the tester
strain. Transformants were incubated for 3 to 5 days at 308C until colonies were
fairly large. Both qualitative and quantitative assays for b-galactosidase activity
were performed as previously described (14, 24). Cells harboring each of the
pGAD-C1, pGAD-C2, pACTII, pMA424, and pBTM116 vectors produced
,0.05 U of b-galactosidase activity. Values for b-galactosidase assays represent
the means for at least three independent transformants. Standard deviations are
indicated.
RNA preparation and Northern analysis. RNA preparation and Northern
analysis were performed as previously described (14). The ratio of CYH2 pre-
mRNA to mRNA was used as an index of the activity of the nonsense-mediated
mRNA decay pathway (12–14). The values presented represent averages from at
least two independent experiments.
Western blot analysis. Western blot analyses, performed as previously de-
scribed (14), were used to monitor fusion protein expression levels. An antihem-
agglutinin (anti-HA) monoclonal antibody (12CA5; Boehringer) was diluted
1:1,000. Horseradish peroxidase-conjugated goat anti-mouse immunoglobulin
G-immunoglobulin M (heavy plus light chains) was diluted 1:5,000. Bound an-
tibodies were detected with the enhanced chemiluminescence system (Amer-
sham) used according to the manufacturer’s instructions.
RESULTS
Identification of Upf1p and Upf3p as proteins that interact
with a dominant-negative fragment of Nmd2p. We previously
demonstrated that overexpression of a GAL4(AD) fusion to a
764-amino-acid C-terminal fragment of Nmd2p (Nmd2DNp)
inhibits the nonsense-mediated mRNA decay pathway in a
dominant manner when the fusion protein is localized to the
cytoplasm but not when it is localized to the nucleus (12).
Amino acid substitutions or deletions in the Upf1p-interacting
domain of this protein do not affect dominant-negative inhibi-
tion of mRNA decay, suggesting that Nmd2DNp interacts not
only with Upf1p but also with at least one additional factor
(14). To identify potential Nmd2DNp-interacting factors, we
used the yeast two-hybrid system (10, 39). DNA encoding the
dominant-negative NMD2DN allele was inserted into a yeast
expression vector in frame with a sequence encoding the DNA-
binding domain of the lexA protein. This plasmid was intro-
duced into the yeast strain L40 (15), which harbors the HIS3
and lacZ genes under the control of promoters containing the
lexA-binding site. Yeast genomic DNA libraries fused, in three
separate frames, to sequences encoding the Gal4p transcrip-
tional activation domain were then screened for cotransform-
ing plasmids which allow the L40 cells to express these two
reporter genes.
Approximately 3 3 106 independent transformants were
screened, and 90 colonies that grew in the absence of histidine
and in the presence of 5 mM 3-aminotriazole and exhibited
b-galactosidase activity were isolated. The library plasmids
from these colonies were rescued and tested for specificity by
retransforming them into the original L40 strain simulta-
neously with either (i) the lexA(DB)-NMD2DN fusion, (ii) a
series of the lexA(DB)-NMD2DN fusions containing deletions
from the C terminus, or (iii) the lexA(DB) vector only. Restric-
tion mapping and partial DNA sequence analysis of plasmids
which passed these specificity tests yielded seven different
genes encoding putative Nmd2DNp-interacting proteins. One
class of clones, as we expected, encoded near-full-length
Upf1p, and a second class of clones encoded a fragment of 236
amino acids from the C terminus of Upf3p (19). The other five
classes of clones encoded either previously identified genes
(SPP41 and RED1) (23, 36) or uncharacterized open reading
frames (YBR270c, YKL023w, and YNR023w). Deletion of
RED1 does not affect nonsense-mediated mRNA decay (data
not shown), and the roles of the other four genes have yet to be
determined. In the experiments described below, we have char-
acterized the interactions between the three principal compo-
nents of the nonsense-mediated mRNA decay pathway, i.e.,
Upf1p, Nmd2p, and Upf3p.
Upf1p and Upf3p interact with distinct domains of Nmd2p.
To determine the regions of Nmd2p responsible for interaction
with Upf1p and Upf3p, we constructed a series of NMD2
deletions and tested their abilities to promote two-hybrid in-
teractions with either UPF1 or UPF3. NMD2 fragments were
fused in frame to the lexA(DB), and the full-length UPF1 and
UPF3 genes were fused in frame to theGAL4(AD). The extent
of interaction between the respective fusion proteins was mon-
itored in cotransformants indirectly, by both a qualitative plate
assay and a quantitative solution assay for b-galactosidase.
These experiments established that coexpression of GAL4
(AD)-UPF1 with all of the lexA(DB)-NMD2 fusions that in-
cluded the 157 C-terminal amino acids of Nmd2p led to the
accumulation of substantial b-galactosidase activity (Fig. 1,
constructs 1 to 9), whereas coexpression of GAL4(AD)-UPF1
with all of the lexA(DB)-NMD2 fusions that lack 166 or more
C-terminal amino acids from Nmd2p yielded background lev-
els of b-galactosidase activity (Fig. 1, constructs 10 to 23).
These results, and earlier studies using different DNA-binding
domain and activation domain fusion constructs (14), support
our previous conclusion that Upf1p interacts with a 157-amino-
acid C-terminal domain of Nmd2p (14) and demonstrate that
Upf1p-Nmd2p two-hybrid interactions are independent of the
nature of the DNA-binding domain and activation domain
fusions utilized. The decreased levels of b-galactosidase activ-
ity obtained with three fusions that retain an intact Nmd2p C
terminus (Fig. 1, constructs 2, 4, and 5) are not indicative of
additional Upf1p-interacting epitopes but rather reflect the
instability of the respective fusion proteins (data not shown).
Cells coexpressing the full-length GAL4(AD)-UPF3 fusion
and the lexA(DB)-NMD2DN(326–1089) fusion accumulated
substantially less b-galactosidase activity than the correspond-
ing Nmd2p-Upf1p fusion pair but nevertheless accumulated
sufficient activity to indicate interaction (Fig. 1, construct 1).
This activity doubled when amino acids 326 to 563 were de-
leted from Nmd2p (Fig. 1, construct 3) and was eliminated
when the DNA-binding domain fusion included only amino
acids 326 to 563 of Nmd2p (Fig. 1, construct 17). These data
suggest that the region of Nmd2p from residue 564 to 1089
must contain the entire Upf3p-interacting domain. To map this
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domain further, the consequences of both N-terminal and C-
terminal deletions of Nmd2p were analyzed. The results ob-
tained from this experiment indicate the following (i) Upf3p
interacts with an Nmd2p domain that is distinct from the
Upf1p-interacting domain, since a construct containing only
the latter did not interact with Upf3p (Fig. 1, construct 9) and
deletion of the Upf1p-interacting domain of Nmd2p had no
effect on its interaction with Upf3p (Fig. 1, constructs 10 and
18; compare to constructs 1 and 3). (ii) The region encom-
passed by Nmd2p residues 564 to 771 contains a major deter-
minant for Upf3p interaction, since the lexA(DB)-NMD2(772–
1089) fusion containing an N-terminal deletion from residue
564 to 771 led to a large decrease of b-galactosidase activity
(Fig. 1, construct 6), the lexA(DB)-NMD2 fusions containing
this region yielded substantial levels of b-galactosidase activity
(Fig. 1, constructs 10 to 14 and 18 to 22), and fusion proteins
with C-terminal truncations of this region lost all detectable
Upf3p interaction activity (Fig. 1, constructs 15 and 23). The
actual N-terminal boundary of this interacting domain could
not be determined because two of the NMD2 fusion proteins
(Fig. 1, constructs 4 and 5) were unstable, regardless of
whether the fusions were to the lexA(DB) or the GAL4(AD)
(data not shown). (iii) The region of Nmd2p from residue 879
to 933 that contains almost the entire acidic domain of Nmd2p
(12, 14) contributes to Upf3p interaction, since deletion of this
region from the respective fusion proteins leads to reduced
levels of b-galactosidase activity (Fig. 1, compare construct 10
to 11 and construct 18 to 19) and since the lexA(DB)-
NMD2(879–1089) fusion yielded detectable levels of b-galac-
tosidase activity (Fig. 1, construct 8). (iv) The region of Nmd2p
from residue 772 to 878 may not contribute to interaction with
Upf3p, since N- or C-terminal deletions into this region had
almost no effect on Nmd2p-Upf3p two-hybrid interaction (Fig.
1, constructs 6 to 8, 11 to 14, and 19 to 22).
Interactions between Upf3p and Nmd2p were also examined
in constructs in which the respective activation domain and
DNA-binding domain fusions were reversed. In support of the
conclusions delineated above, results qualitatively identical to
those presented in Fig. 1 were obtained (data not shown).
An internal domain of Upf3p encompassing residues 78 to
278 is the major determinant for interaction with Nmd2p.
UPF3 was identified as a gene encoding an Nmd2DNp-inter-
acting protein (see above), and the respective Upf3p region(s)
responsible for such interaction was determined by analyzing
the activities of deletion derivatives in the two-hybrid system.
UPF3 fragments were fused in frame to the lexA(DB), and the
NMD2 fragment that contains the entire Upf3p-binding site,
i.e., that from residue 564 to 1089 (Fig. 1), was fused in frame
to the GAL4(AD). As shown in Fig. 2, coexpression of the
GAL4(AD)-NMD2(564–1089) fusion with either the full-
length lexA(DB)-UPF3 fusion (Fig. 2, construct 1) or lex-
A(DB)-UPF3 fusions containing N-terminal deletions of either
31 or 77 amino acids (Fig. 2, constructs 2 and 3) yielded
substantial levels of b-galactosidase activity. A lexA(DB) fusion
containing a deletion of 151 amino acids from the Upf3p N
terminus led to a significant decrease of b-galactosidase activ-
ity (Fig. 2, construct 4), and fusions containing deletions of
either 204 or 279 amino acids from the Upf3p N terminus
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yielded background levels of b-galactosidase activity (Fig. 2,
constructs 5 and 6). Comparable effects of N-terminal dele-
tions were observed with Upf3p fragments that also contain
C-terminal truncations (Fig. 2, constructs 7, 10, and 11 and
constructs 8, 13, and 14). These results indicate that (i) two
regions of Upf3p, from residue 78 to 151 and from residue 152
to 204, must contain important Nmd2p-interacting epitopes
and (ii) the N-terminal 77 amino acids of Upf3p do not con-
tribute to the interaction with Nmd2p, and their presence in
the fusion proteins may inhibit such an interaction to some
extent.
C-terminal deletions of UPF3 provided further definition of
its Nmd2p-interacting domain. lexA(DB)-UPF3 fusions con-
taining C-terminal deletions of 109 or 183 amino acids pro-
moted almost twofold increases in b-galactosidase activity, rel-
ative to that of the full-length fusion (Fig. 2, constructs 7 and
8), whereas the fusion containing a deletion of 236 amino acids
from the Upf3p C terminus yielded background levels of b-ga-
lactosidase (Fig. 2, construct 9). These results underscore the
importance of Upf3p residues 152 to 204 in Nmd2p binding.
Moreover, these results, and those demonstrating the conse-
quences of C-terminal truncation of Upf3p fragments which
also contain N-terminal deletions (Fig. 2, constructs 10 to 15),
further suggest that the C-terminal 109 amino acids of Upf3p
do not contribute to Nmd2p interaction and may actually in-
hibit Nmd2p-Upf3p interaction. Taken together, the results in
Fig. 2 indicate that the region of Upf3p from residue 78 to 204
is necessary for Nmd2p interaction.
Interactions between Upf3p and Nmd2p were also examined
in constructs in which the lexA(DB) and GAL4(AD) fusions
were reversed. Results essentially identical to those shown in
Fig. 2 were obtained except that we did detect a weak interac-
tion between lexA(DB)-NMD2(564–1089) and a GAL4(AD)-
UPF3 fusion containing a deletion of 204 amino acids from its
N terminus (the latter being the homolog of construct 5 in Fig.
2) (data not shown). This observation suggests that the region
from Upf3p residue 205 to 279 may also contribute to Upf3-
Nmd2p interaction, a conclusion further supported by the ob-
servation that the lexA(DB) fusion harboring UPF3 residues 78
to 278 demonstrated the highest level of b-galactosidase activ-
ity when tested for interaction with GAL4(AD)-NMD2(564–
1089) (Fig. 2, construct 11). Thus, we conclude that an internal
region of Upf3p, comprised of residues 78 to 278, is the major
determinant for interaction with Nmd2p.
The Zn21 finger-like motifs in Upf1p are necessary but not
sufficient for interaction with Nmd2p.We previously identified
NMD2 as a gene encoding a Upf1p-interacting protein and
localized its Upf1p-interacting domain to a 157-amino-acid
segment at its carboxyl terminus (12, 14). To determine the
region(s) of Upf1p responsible for interaction with Nmd2p, we
constructed a series of Upf1p deletion derivatives and tested
their abilities to interact with Nmd2p in the two-hybrid system.
FIG. 1. Two-hybrid interactions and dominant-negative activities of Nmd2p
fragments. (A and B). Upf1p, Upf3p, and at least one other factor interact with
distinct regions of Nmd2p. The yeast two-hybrid system was used to identify the
Upf1p- and Upf3p-interacting domains within Nmd2p, using the tester strain
L40. A GAL4(AD)-UPF1(1–971) fusion and a GAL4(AD)-UPF3(1–387) fusion
were used to test for interactions with each of 23 lexA(DB)-NMD2 fusions
encoding distinct fragments of Nmd2p. Individual transformants were selected,
and b-galactosidase activity was determined (see Materials and Methods). (A)
Quantitative liquid assay for b-galactosidase activity. NMD2 sequences fused to
the lexA(DB) are illustrated on the left. The small black box represents the
putative transmembrane helix (14), and the hatched black and hatched open
boxes represent the acidic and the Upf1p-interacting domains, respectively. The
grey and open boxes in constructs 2 to 23 represent lexA(DB)-NMD2 fusions
that, respectively, do or do not interact with Upf3p. Upf1p Interaction and Upf3p
Interaction depict the respective b-galactosidase activities (means 6 standard
deviations) for at least three independent assays performed on cultures derived
from individual colonies. Dominant Inhibition depicts the ratio of CYH2 pre-
mRNA to mRNA determined in panel C by Northern blotting. Asterisks depict
fusion proteins shown by Western blotting to be significantly less abundant than
that encoded by construct 1. (B) Qualitative b-galactosidase assay, on X-Gal-
containing plates, for Upf3p interaction only. (C) Identification of regions of
Nmd2p responsible for dominant-negative inhibition. Each of the NMD2 frag-
ments shown in panel A was fused in frame to a GAL4(AD) in which the nuclear
localization signal had been deleted. Total RNA was isolated from HFY1200 (a
wild-type NMD2 strain) overexpressing each of the respective fusion proteins.
RNA was fractionated by gel electrophoresis and analyzed by Northern blotting,
using the 0.6-kb EcoRI-HindIII fragment of the CYH2 gene as a probe. Lanes:
WT, RNA from HFY1200 harboring pACTII(DNLS) only; 1 to 23, RNAs from
HFY1200 overexpressing each of the GAL4(AD)-NMD2 fusion proteins that
contain the corresponding fragments shown in panel A. CYH2 pre-mRNA/
mRNA ratios from the blot are summarized in the last column of panel A.
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Here, the UPF1-containing fragments were fused in frame to
the GAL4(AD), and the NMD2 fragment that contains the
entire Upf1p-interacting domain (residues 933 to 1089) was
fused in frame to the GAL4(DB). As shown in Fig. 3, coex-
pression of the GAL4(DB)-NMD2(933–1089) fusion with full-
length GAL4(AD)-UPF1 (Fig. 1, construct 1) or GAL4(AD)
fusions harboring UPF1 fragments with C-terminal deletions
up to residue 181 (Fig. 3, constructs 2 to 7) all led to the
accumulation of substantial b-galactosidase activity. GAL4
(AD) fusions harboring internal UPF1 fragments from resi-
dues 62 to 289, 62 to 207, and 62 to 181 (Fig. 3, constructs 9 to
11) also showed significant two-hybrid activity, but that activity
was three- to sixfold less than that of the aforementioned UPF1
fusions. This decrease in activity was specific for interaction
with Nmd2p, since the same deletions had no effect on Upf1p
homodimerization (12a). In contrast, no detectable b-galacto-
sidase activity was observed when the GAL4(DB)-NMD2(933–
1089) fusion was coexpressed with (i) a GAL4(AD) fusion
harboring a UPF1 fragment with a C-terminal deletion up to
residue 153 (Fig. 3, construct 8), (ii) GAL4(AD) fusions har-
boring UPF1 fragments with N-terminal deletions of either 290
or 556 residues (Fig. 3, constructs 13 and 14), or (iii)
GAL4(AD) fusions harboring internal UPF1 fragments from
residues 62 to 153 (data not shown), 80 to 289 (Fig. 3, construct
12), 80 to 207, and 80 to 181 (data not shown). These results
indicate that the N-terminal 181 amino acids of Upf1p contain
the major determinant(s) for interaction with Nmd2p. This
region includes, but is not limited to, amino acids comprising
the Zn21 finger-like motifs within Upf1p (1, 18, 22), indicating
that they are essential but not sufficient for interaction with
Nmd2p. These conclusions were substantiated by observations
that internal deletions of Upf1p from residue 62 to 152 or 152
to 289 completely abolished Upf1p-Nmd2p interaction while
deletions of residues 290 to 425, 426 to 553, 554 to 608, 609 to
789, and 790 to 806 had essentially no effect on such interaction
(data not shown).
Upf1p and Upf3p interact in the two-hybrid system. Using
the yeast two-hybrid system, we have characterized Upf1p-
Nmd2p and Nmd2p-Upf3p interactions (see above and refer-
ences 12 and 14). We were also interested in determining
whether Upf1p-Upf3p interactions could be detected with this
system, and we used two sets of constructs to test this possi-
bility. In one experiment, we assayed the ability of a full-length
lexA(DB)-UPF3 fusion to interact with a panel of GAL4(AD)-
UPF1 fusions (Fig. 3, constructs 1 to 14). When coexpressed
with lexA(DB)-UPF3, all of the GAL4(AD)-UPF1 fusions that
are capable of interacting with GAL4(DB)-NMD2(933–1089)
yielded detectable levels of b-galactosidase activity (Fig. 3,
constructs 1 to 7 and 9 to 11). Of these, the highest levels of
activity were observed with GAL4(AD) fusions containing
UPF1 fragments from residues 1 to 666, 1 to 207, and 62 to 207
(Fig. 3, constructs 2, 6, and 10). All of the GAL4(AD)-UPF1
fusions that are not capable of interacting with GAL4(DB)-
NMD2(933–1089) yielded only background levels of b-galac-
tosidase activity (Fig. 3, constructs 8 and 12 to 14). These
results suggest that Upf1p and Upf3p do interact in this assay
FIG. 2. Identification of Upf1p- and Nmd2p-interacting domains within Upf3p. The yeast two-hybrid system was used to identify the Upf1p- and Nmd2p-interacting
domains within Upf3p, using the tester strain L40. A GAL4(AD)-NMD2(564–1089) fusion and a GAL4(AD)-UPF1(1–971) fusion were used to test for interaction with
each of 15 lexA(DB)-UPF3 fusions encoding distinct fragments of Upf3p (Nmd2p Interaction and Upf1p Interaction [column a], respectively). Interaction between the
GAL4(AD)-UPF1(1–971) fusion and each of the lexA(DB)-UPF3 fusions was also assayed with strain L40 harboring a plasmid that overexpresses a fragment of NMD2
from residue 564 to 1089 (Upf1p Interaction [column b]). Individual transformants were selected, and b-galactosidase activity was determined quantitatively in a liquid
assay. UPF3 sequences fused to the lexA(DB) are illustrated. The black boxes in construct 1 represent the three putative bipartite nuclear localization signals. The grey
and open boxes in constructs 2 to 15 represent lexA(DB)-UPF3 fusions that, respectively, do or do not interact with Nmd2p. Interaction values depict mean
b-galactosidase activities6 standard deviations for at least three independent assays performed on cultures derived from individual colonies. The asterisk in the Nmd2p
interaction column for construct 5 indicates that weak b-galactosidase activity was detected from this construct when the AD and DB vectors were reversed.
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and that the Upf3p- and Nmd2p-interacting domains within
Upf1p overlap or are identical to each other.
We also tested the ability of the full-length GAL4(AD)-
UPF1 fusion to interact with a panel of lexA(DB)-UPF3 fusions
(Fig. 2, constructs 1 to 15). When coexpressed with full-length
GAL4(AD)-UPF1, all but two of the lexA(DB)-UPF3 fusions
that are capable of interacting with GAL4(AD)-NMD2(564–
1089) accumulated b-galactosidase activity, although to con-
siderably lesser extents (Fig. 2, constructs 1 to 4, 7, 10, 11, and
13); all of the lexA(DB)-UPF3 fusions that do not interact with
GAL4(AD)-NMD2(564–1089) yielded background levels of
b-galactosidase activity (Fig. 2, constructs 5, 6, 9, 12, and 15).
These results indicate that Upf1- and Nmd2p-interacting do-
mains within Upf3p also overlap or are identical to each other.
Two-hybrid interactions of Upf1p-Nmd2p, Nmd2p-Upf3p,
and Upf1p-Upf3p in the absence of genomic UPF1, NMD2, or
UPF3. The two-hybrid approach does not distinguish between
direct and indirect interactions. For example, Upf3p could
associate with Upf1p by using Nmd2p as a bridging molecule.
We therefore repeated a subset of the previous two-hybrid
assays with isogenic strains with UPF1, NMD2, or UPF3 individ-
ually deleted. Upf1p-Nmd2p and Nmd2p-Upf3p interactions
were tested with the GAL4(AD)-UPF1(1–971)/lexA(DB)-
NMD2DN(326–1089) and lexA(DB)-NMD2DN(326–1089)/
GAL4(AD)-UPF3(1–387) fusion pairs, respectively. Interac-
tions between Upf1p and Upf3p were tested with both a
weakly interacting pair of fusion proteins [lexA(DB)-UPF3(1–
387)/GAL4(AD)-UPF1(1–971)] and a more effectively inter-
acting pair [lexA(DB)-UPF3(1–387)/GAL4(AD)-UPF1(1–207).
These experiments showed that in upf1D and upf3D strains, all
of the tested interactions occur as well as they do in wild-type
cells (Table 5), indicating that they do not require the UPF1
and UPF3 gene products. Likewise, deletion of the NMD2 gene
had no effect on Upf1p-Nmd2p or Nmd2p-Upf3p interactions
(Table 5). However, nmd2D cells were completely incapable of
supporting either pair of Upf1p-Upf3p interactions (Tables 5
and 6). These results imply that Nmd2p can bind Upf1p and
FIG. 3. Identification of Nmd2p- and Upf3p-interacting domains within Upf1p. The yeast two-hybrid system was used to identify Nmd2p- and Upf3p-interacting
domains within Upf1p. To test for interaction between Upf1p and Nmd2p, a GAL4(DB)-NMD2(933-–1089) fusion that contains the entire Upf1p-interacting domain
of Nmd2p was cotransformed into the tester strain GGY1::171 with each of 14 GAL4(AD)-UPF1 fusions encoding distinct fragments of Upf1p. To test for interactions
between Upf1p and Upf3p, a lexA(DB)-UPF3(1–387) fusion was cotransformed with each of 14GAL4(AD)-UPF1 fusions into strain L40. Individual transformants were
selected, and b-galactosidase activity was determined quantitatively in a liquid assay. UPF1 sequences fused to the GAL4(AD) are illustrated. The hatched boxes and
black boxes shown in construct 1 represent the two putative Zn21 fingers and seven conserved motifs common to the members of helicase superfamily I, respectively
(1, 18, 22). The grey and open boxes in constructs 2 to 14 represent GAL4(AD)-UPF1 fusions that, respectively, do or do not interact with Nmd2p and Upf3p.
Interaction values depict mean b-galactosidase activities 6 standard deviations for at least three independent assays performed on cultures derived from individual
colonies.
TABLE 5. Upf1p-Nmd2p, Nmd2p-Upf3p, and Upf1p-Upf3p
two-hybrid interactions in the absence of genomic
UPF1 NMD2, or UPF3a
Strain
b-Galactosidase activity for the following
interaction (bait-prey)
Upf1p-Nmd2p Nmd2p-Upf3p Upf3p-Upf1p
Wild type 1 1 1
upf1D 1 1 1
nmd2D 1 1 2
upf3D 1 1 1
a The construction of tester strains containing single deletions of UPF1,
NMD2, and UPF3 is described in Materials and Methods. The fusion constructs
lexA(DB)-NMD2DN(326–1089)/GAL4(AD)-UPF1(1–971) and lexA(DB)-NMD2DN
(326–1089)/GAL4(AD)-UPF3(1–387) were used to examine interactions between
Upf1p and Nmd2p and between Nmd2p and Upf3p, respectively. Constructs
encoding the fusion pairs lexA(DB)-UPF3(1–387)/GAL4(AD)-UPF1(1–971)
(weak interactors) and lexA(DB)-UPF3(1–387)/GAL4(AD)-UPF1(1–207) (mod-
erately strong interactors) were used to examine interactions between Upf1p and
Upf3p. b-Galactosidase activity was determined qualitatively by replica plating
on X-Gal-containing plates. 1, blue color development; 2, no color develop-
ment (after 7 days of incubation at 308C).
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Upf3p simultaneously and promote the formation of a Upf1p-
Nmd2p-Upf3p complex in vivo.
Overexpression of Nmd2p enhances the formation of a
Upf1p-Nmd2p-Upf3p complex. The data described above sug-
gest that Nmd2p bridges the apparent interaction between
Upf1p and Upf3p. To test this hypothesis further, we asked
whether overexpression of Nmd2p could alter the extent of the
Upf1p-Upf3p two-hybrid interaction. A series of plasmids ex-
pressing either full-length Nmd2p or fragments thereof were
introduced into yeast cells coexpressing either of two pairs of
fusion proteins, lexA(DB)-UPF3(1–387)/GAL4(AD)-UPF1(1–
971) or lexA(DB)-UPF3(1–387)/GAL4(AD)-UPF1(1–207). In
the wild-type NMD2 background, the level of b-galactosidase
activity was low for both pairs of interactors (although signif-
icantly better for the pair including truncated Upf1p) (Table
6). However, when full-length NMD2, or a fragment of NMD2
including residues 564 to 1089, was overexpressed, yeast strains
containing both pairs of interactors showed approximately 10-
to 100-fold increases in b-galactosidase activity. In contrast,
overexpression of Nmd2p fragments that contain deletions of
either the Upf1p-interacting domain (NMD2-CD166) or both
the Upf1p- and Upf3p-interacting domains (NMD2-CD526)
had no effect on the level of b-galactosidase activity (Table 6).
These data indicate that overexpression of Nmd2p can en-
hance the formation of a Upf1p-Nmd2p-Upf3p complex in
vivo and that this activity is dependent on the presence of
intact Upf1p- and Upf3p-interacting domains within Nmd2p.
We also introduced a plasmid overexpressing a fragment of
Nmd2p from residues 564 to 1089 into yeast strains containing
the GAL4(AD)-UPF1(1–971) fusion and each of a panel of
lexA(DB)-UPF3 fusions (Fig. 2, constructs 1 to 15). As shown
in Fig. 2, levels of b-galactosidase activity were significantly
increased in yeast strains expressing lexA(DB)-UPF3 fusion
proteins previously shown to be capable of interacting with
Nmd2p (Fig. 2, constructs 1 to 4, 7, 8, 10, 11, 13, and 14).
However, levels of b-galactosidase activity were not increased
in yeast strains expressing lexA(DB)-UPF3 fusion proteins pre-
viously shown to be incapable of interacting with Nmd2p (Fig.
2, constructs 5, 6, 9, 12, and 15). This indicates that the for-
mation of a Upf1p-Nmd2p-Upf3p complex is also dependent
on the ability of Upf3p to interact with Nmd2p. Comparable
experiments showed that UPF1 deletions that disrupt of the
ability of Upf1p to interact with Nmd2p also abolish complex
formation (data not shown). Collectively, these results rein-
force the conclusion that Nmd2p is a bridging molecule and
that the two-hybrid Upf1p-Upf3p interaction must be indirect.
Single or multiple deletions of UPF1, NMD2, and UPF3
inhibit nonsense-mediated mRNA decay to the same extent.
The results of our two-hybrid analyses (see above and refer-
ences 12 and 14) strongly suggest that Upf1p, Nmd2p, and
Upf3p function either as a complex or in closely related steps
of the nonsense-mediated mRNA decay pathway. This conclu-
sion was strengthened by analyzing the nonsense-mediated
mRNA decay phenotypes associated with single or multiple
deletions of the genes encoding each of these proteins. To this
end, we constructed yeast strains containing either single de-
letions of UPF1, NMD2, and UPF3, double deletions of UPF1/
NMD2, NMD2/UPF3, and UPF1/UPF3, or a triple deletion of
all three genes (see Materials and Methods). Total RNA was
isolated from yeast strains containing these deletions, and
Northern blot analysis was used to monitor the levels of the
CYH2 pre-mRNA, an endogenous nonsense-containing
mRNA (12, 13). Northern analysis demonstrated that the
abundance of the CYH2 pre-mRNA increased to equal extents
in strains carrying the single deletions, the double deletions, or
the triple deletion (Fig. 4).
Both the N-terminal Upf3p-binding site and a region includ-
ing residues 772 to 816 of Nmd2p are required for dominant
inhibition of nonsense-mediated mRNA decay. We have pre-
viously shown that overexpression of a GAL4(AD) fusion to a
764-amino-acid C-terminal fragment of Nmd2p can inhibit the
nonsense-mediated mRNA decay pathway in a dominant man-
ner when the fusion protein is localized to the cytoplasm but
not when it is localized to the nucleus (12). Recently, we
demonstrated that the dominant-negative effects of this nmd2
allele are independent of its Upf1p-binding activity, since a
deletion of the entire Upf1p-interacting domain of Nmd2p had
no effect on the inhibition of mRNA decay (14). To determine
the region(s) responsible for the dominant-negative effects, we
examined the inhibitory activity of the panel of NMD2 frag-
ments shown in Fig. 1A. Each of these fragments was cloned
into an expression vector and overexpressed in an NMD2 wild-
type strain as described previously (14). Northern blot analysis
of the relative levels of the CYH2 pre-mRNA and mRNA was
used to monitor the activity of the nonsense-mediated mRNA
decay pathway in each of the transformants. As shown in Fig.
1A and C, N-terminal deletions of Nmd2p up to residue 563
have no significant effects on dominant-negative activity (con-
structs 1 to 3). However, N-terminal deletions extending to
residue 771 lead to a complete loss of inhibitory activity (Fig.
1A and C constructs 4 to 6), indicating that the region spanning
residues 564 to 771 is required for dominant inhibition. NMD2
fragments containing C-terminal deletions up to residue 816
still inactivated nonsense-mediated mRNA decay as efficiently
as the original dominant-negative nmd2 allele (Fig. 1A and C,
compare construct 1 to constructs 10 to 12 and 18 to 20),
indicating that the region from residue 817 to 1089, which
includes the entire acidic domain and the entire Upf1p-inter-
acting domain of Nmd2p, is not required for dominant inhibi-
tion. In contrast, further C-terminal deletions up to Nmd2p
residue 771 lead to a complete loss of inhibitory activity (Fig.
1A and C, constructs 13, 14, 21, and 22), indicating that the
TABLE 6. Overexpression of NMD2 enhances two-hybrid
interaction between Upf1p and Upf3pa
Strain
b-Galactosidase activity (U) for:
lexA-UPF3(1–387)/
GAL4(AD)-
UPF1(1-971)
lexA-UPF3(1-387)/
GAL4(AD)-
UPF1(1-207)
NMD2 0.35 6 0.03 3.00 6 0.40
NMD2[NMD2] 3.10 6 0.30 33.60 6 3.90
NMD2[NMD2DN] 43.30 6 3.00 69.30 6 5.70
NMD2[NMD2-CD166] 0.30 6 0.04 3.50 6 0.80
NMD2[NMD2-CD526] 0.30 6 0.05 2.70 6 0.30
nmd2D #0.05 #0.05
a Two-hybrid interaction between Upf1p and Upf3p was assayed in strains
overexpressing the NMD2 gene or fragments of NMD2. Constructs expressing
lexA(DB)-UPF3(1–387)/GAL4(AD)-UPF1(1–971) (weak interactors) and lex-
A(DB)-UPF3(1–387)/GAL4(AD)-UPF1(1–207) (moderately strong interactors)
were tested. NMD2[NMD2], strain overexpressing full-length NMD2;
NMD2[NMD2DN], strain overexpressing the original dominant-negative frag-
ment encoding Nmd2p residues 326 to 1089; NMD2[NMD2-CD166], strain over-
expressing NMD2-CD166, a construct that encodes a 166-amino-acid deletion
from the Nmd2p C terminus; NMD2[NMD2-CD526], strain overexpressing
NMD2-CD526, a construct that encodes a 526-amino-acid deletion from the
Nmd2p C terminus. NMD2 and its derivatives contain N-terminal triple-HA tags,
and their expression was driven by the ADH1 promoter on a centromere-based
vector, pRS313. Individual transformants were selected, and b-galactosidase
activity was determined quantitatively in a liquid assay. b-Galactosidase activities
from wild-type (NMD2) and nmd2D strains are also shown. Values represent the
means 6 standard deviations for at least three independent assays performed on
cultures derived from individual colonies.
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region from residue 772 to 816 is also required for dominant
inhibition.
Although residues 564 to 771 and 772 to 816 are required for
dominant inhibition, overexpression of NMD2 fragments con-
taining either region alone is not sufficient to inactivate non-
sense-mediated mRNA decay (Fig. 1A and C, constructs 6 and
22). Because the NMD2 fragment containing both regions can
inactivate nonsense-mediated mRNA decay efficiently (Fig. 1A
and C, construct 20), we conclude that the Nmd2p domain
encompassing residues 564 to 816 is responsible for the dom-
inant-negative effect. Interestingly, this region spans residues
that are required (residues 564 to 771) as well as residues that
are not required (residues 772 to 816) for Nmd2p binding to
Upf3p (see above).
Overexpression of Upf3p alone is not sufficient to alleviate
the dominant-negative effects of Nmd2DNp. Since the minimal
dominant-negative fragment of Nmd2p includes a Upf3p-bind-
ing site (see above), it is formally possible that the dominant-
negative effect is attributable to the saturation of functional
Upf3p with nonfunctional Nmd2p. To test this possibility, we
transformed a series of plasmids expressing UPF3 or epitope-
tagged UPF3 into yeast cells containing a dominant-negative
nmd2 allele. The results of these experiments are shown in Fig.
5. In cells containing the dominant-negative nmd2 allele, ex-
pression of UPF3 from a single-copy or a high-copy-number
plasmid had no effect on dominant-negative inhibition (Fig.
5B, lanes 3 and 4). Furthermore, there was no effect on dom-
inant inhibition when Upf3p expression from a high-copy-
number plasmid was enhanced by replacing the normal UPF3
promoter with the more potent ADH1 promoter (Fig. 5B, lanes
5 and 6). In contrast, expression of NMD2 from a single-copy
or a high-copy-number plasmid or expression of HA-NMD2
from the ADH1 promoter on a high-copy-number plasmid led
to a dosage-dependent increase of nonsense-mediated mRNA
decay activity (Fig. 5A, lanes 3 to 5). These results indicate that
the dominant-negative effect of Nmd2p is targeted to another
interacting component that is distinct from Upf3p.
DISCUSSION
Nonsense-mediated mRNA decay is dependent on the activ-
ity of the interacting components Upf1p, Nmd2p, and Upf3p.
UPF1, NMD2/UPF2, and UPF3 are the three principal nones-
sential genes whose products have been shown to be required
for the selective decay of only those transcripts in S. cerevisiae
that contain premature translational termination codons (for a
review, see reference 16). While structural and biochemical
analyses suggest that Upf1p may be an RNA-binding protein
with ATPase and RNA helicase activities (1, 7, 18, 22), little
else is known about the functions of these factors. As an ap-
proach to elucidating their respective roles in mRNA decay,
we have begun to identify the proteins with which these factors
interact and to define the relevant interacting domains. Thus,
in earlier studies, we showed that Upf1p and Nmd2p are in-
teracting proteins, localized the Upf1p-interacting domain of
Nmd2p to its 157-amino-acid C terminus, demonstrated that
interaction between Upf1p and Nmd2p is required for non-
sense-mediated mRNA decay, and established that at least one
other factor must interact with Nmd2p (12, 14). Here, we
sought to identify the other factor(s) and used the yeast two-
hybrid system to show that both UPF1 and UPF3 encode
Nmd2p-interacting proteins and that NMD2 encodes a Upf3p-
interacting protein (12a). Interactions between Nmd2p and
Upf3p have also been reported recently (37). Further evidence
for these interactions was provided by experiments that de-
fined specific Nmd2p-interacting domains within Upf1p and
Upf3p and specific Upf1p- and Upf3p-interacting domains
within Nmd2p (Fig. 1 to 3), as well as by experiments which
showed that cells harboring single or multiple deletions of
UPF1, NMD2, and UPF3 inhibit nonsense-mediated mRNA
decay to the same extent (Fig. 4) (5, 12, 19). Collectively, these
data demonstrate that Upf1p, Nmd2p, and Upf3p are inter-
acting components of the yeast nonsense-mediated mRNA
decay pathway.
Two-hybrid interactions between Upf1p and Upf3p are in-
direct and are bridged by Nmd2p. Our two-hybrid analyses
identified Upf1p-Nmd2p, Nmd2p-Upf3p, and Upf1p-Upf3p
interactions (Fig. 1 to 3) (12, 14). To determine whether the
observed pairwise interactions require the respective third
components, we examined the consequences that deleting
genomic copies of UPF1, NMD2, and UPF3 had on the out-
come of two-hybrid experiments. We find that single deletion
of UPF1, NMD2, or UPF3 has no effect on Upf1p-Nmd2p or
Nmd2p-Upf3p interactions, indicating that they occur without
the participation of the absent factor (Table 5). However,
deletion of NMD2 completely abolishes the apparent interac-
tion between Upf1p and Upf3p (Tables 5 and 6), indicating
that this interaction in wild-type cells is indirect and is bridged
by Nmd2p. Further evidence for this conclusion includes the
FIG. 4. Single or multiple deletions of UPF1, NMD2, and UPF3 have iden-
tical nonsense-mediated mRNA decay phenotypes. Total RNA was isolated from
yeast cells containing single or multiple deletions of UPF1, NMD2, and UPF3.
The construction of these strains is described in Materials and Methods. North-
ern blotting was performed as described in the legend to Fig. 1. CYH2 pre-
mRNA/mRNA ratios from these cells are summarized. WT, wild type.
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following: (i) overexpression of either full-length Nmd2p or its
dominant-negative fragment enhances the apparent interac-
tion of Upf1p and Upf3p by 10- to 200-fold (Table 6 and Fig.
2); (ii) this enhancement is dependent on the presence of intact
Upf1p- and Upf3p-interacting domains within Nmd2p and on
the ability of Upf1p and Upf3p to interact with Nmd2p (Table
6 and Fig. 2 and data not shown); (iii) the domains of Upf1p
and Upf3p putatively involved in the interaction with each
other correspond to the domains on the two proteins which
interact with Nmd2p (Fig. 2 and 3); and (iv) a two-hybrid
screen with Upf1p as bait failed to identify Upf3p as a Upf1p-
interacting protein, and a two-hybrid screen with Upf3p as bait
failed to identify Upf1p as a Upf3p-interacting protein, but
both screens identified Nmd2p an interacting partner (12, 12a).
The fact that Nmd2p is required for the observed interaction
between Upf1p and Upf3p indicates that Nmd2p can interact
with both Upf1p and Upf3p simultaneously and that it may
promote the formation of a Upf1p-Nmd2p-Upf3p complex in
vivo. Experiments demonstrating that all three proteins are
predominantly localized to the cytoplasm support this possi-
bility (3, 12b, 26), but coimmunoprecipitation or cross-linking
experiments are necessary for definitive identification of such a
complex.
When assaying the two-hybrid interactions between Upf1p
and Upf3p in NMD2 wild-type cells, we observed that a subset
of truncations in either Upf1p or Upf3p led to a significant
increase of b-galactosidase activity (Fig. 2, constructs 2, 3, 7,
10, and 11; Fig. 3, constructs 2, 6, and 10). Each of these Upf1p
or Upf3p fragments led to considerably more b-galactosidase
activity than the respective full-length polypeptide. Such in-
creases may simply reflect the loss of polypeptide sequences
that interfere with two-hybrid interactions (e.g., masking do-
mains or possible cytoplasmic retention signals), or they may
indicate that binding of these Upf1p or Upf3p fragments to
Nmd2p results in a conformational change in Nmd2p that, in
turn, promotes increased binding of Nmd2p to Upf3p or
Upf1p. The enhancement of Upf3p interaction by some N-
terminal deletions of Nmd2p may be attributable to similar
effects (Fig. 1, constructs 3 and 18).
Novelty of the protein domains involved in Upf1p-Nmd2p
and Nmd2p-Upf3p interactions. To delineate the domains es-
sential for Upf1p-Nmd2p and Nmd2p-Upf3p interactions, we
FIG. 5. Overexpression of NMD2, but not UPF3, can alleviate the dominant-negative effects of Nmd2DNp. (A) Overexpression of NMD2 alleviates, in a
dosage-dependent manner, the inhibition of mRNA decay caused by a dominant-negative allele of NMD2. Plasmids expressing a wild-type (WT) or HA-tagged NMD2
gene were transformed into yeast cells expressing the dominant-negative allele ofNMD2. Total RNA was isolated from these cells, and Northern blotting was performed
as described in the legend to Fig. 1. Lane 1, RNA from HFY1200 harboring pACTII(DNLS) only; lane 2, HFY1200 harboring pACTII-NMD2DN; lane 3, HFY1200
harboring pACTII-NMD2DN and pRS314-NMD2; lane 4, HFY1200 harboring pACTII-NMD2DN and YEplac112-NMD2; lane 5, HFY1200 harboring pACTII-
NMD2DN and YEplac112-ADH1p-HA-NMD2. CYH2 pre-mRNA/mRNA ratios from these cells are summarized below the blot. (B) Overexpression of UPF3 cannot
alleviate the inhibition of mRNA decay caused by a dominant-negative allele of NMD2. Plasmids expressing wild-type or epitope-tagged UPF3 genes were individually
transformed into yeast cells expressing the dominant-negative allele of NMD2. Total RNA was isolated from these cells, and Northern blotting was performed as
described in the legend to Fig. 1. Lane 1, RNA from HFY1200 harboring pACTII(DNLS) only; lane 2, HFY1200 harboring pACTII-NMD2DN; lane 3, HFY1200
harboring pACTII-NMD2DN and pRS314-UPF3; lane 4, HFY1200 harboring pACTII-NMD2DN and YEplac112-UPF3; lane 5, HFY1200 harboring pACTII-NMD2DN
and YEplac112-ADH1p-FLAG-UPF3; lane 6, HFY1200 harboring pACTII-NMD2DN and YEplac112-ADH1p-HA-UPF3. CYH2 pre-mRNA/mRNA ratios from these
cells are summarized below the blot. S.C., single copy; H.C., high copy.
1592 HE ET AL. MOL. CELL. BIOL.
 at UNIV O
F M
ASS M
ED SCH on August 15, 2008 
m
cb.asm
.org
D
ow
nloaded from
 
used qualitative and quantitative two-hybrid analysis of dele-
tion mutants of the respective genes. These experiments indi-
cate the following. (i) None of the interacting domains identi-
fied in this study has significant sequence homology with
known protein-protein interaction motifs, except for the
Nmd2p-interacting domain of Upf1p and a weaker Upf3p-
interacting domain of Nmd2p (see below). They may thus
represent new classes of such structures. (ii) Upf1p and Upf3p
interact with distinct domains of Nmd2p. The Upf1p-interact-
ing domain of Nmd2p was previously mapped to a 157-amino-
acid segment at its C terminus in which two regions, spanning
residues 947 to 985 and 1034 to 1061, appear to be the prin-
cipal Upf1p-interacting epitopes (14). The major Upf3p-inter-
acting domain is located within Nmd2p residues 564 to 771,
and a weaker domain is localized to a region from residue 879
to 933. The latter domain, which includes almost all of the
hyperacidic domain of Nmd2p (12), enhances binding to
Upf3p (Fig. 1A, constructs 10 and 18) but also appears to
inhibit interaction with Upf1p (14). Hyperacidic domains have
been found in a number of other proteins, such as nucleolins
and transcription factors, and their functions are largely un-
known (17). If the hyperacidic domain is actually involved in
regulating Nmd2p-Upf3p interaction, it is likely to do so via
interaction with a region of clustered positive charge in Upf3p.
In this regard, it should be noted that in a two-hybrid assay for
interaction with the hyperacidic domain of Nmd2p, the C-
terminal 256-amino-acid segment of Upf3p, which contains
multiple lysine-argine-rich regions (19), yielded the same level
of b-galactosidase activity as did full-length Upf3p (data not
shown). (iii) The Zn21 finger-like motifs of Upf1p, encom-
passed within residues 62 to 152 (1, 22), are necessary but not
sufficient for interaction with Nmd2p. Deletion analysis indi-
cates that residues 62 to 181, which include the two Zn21 finger
motifs and a short flanking region, comprise the minimal do-
main sufficient for interaction with Nmd2p (Fig. 3). Although
Zn21 finger motifs in other proteins have been implicated in
both DNA and RNA binding (4), our results indicate that
these motifs are also involved in both heterodimerization with
Nmd2p (see above) and homodimerization (12a). This region
of Upf1p, like that recently identified in the RAG1 protein
(29), thus may represent a structure that is distinct from that of
the classical Zn21 finger motif and may exemplify a new class
of protein-protein interaction domains.
Dominant-negative Nmd2p targets a factor other than
Upf1p or Upf3p. Overexpression of a protein comprised of a
764-amino-acid C-terminal fragment of Nmd2p fused to the
GAL4(AD) has a dominant-negative effect on nonsense-medi-
ated mRNA decay when the protein is localized in the cyto-
plasm but not when it is localized in the nucleus (12). Since
deletion or point mutations in the Upf1p-interacting domain of
this fragment, or overexpression of Upf1p, do not alter dom-
inant-negative inhibition, we have concluded that the inhibi-
tory effects on mRNA decay arise from Nmd2p interaction
with a factor other than Upf1p (14). Further deletion mapping
has shown that two regions of Nmd2p, spanning residues 564
to 771 and 772 to 816, are required for dominant-negative
activity and that neither domain alone is sufficient for such
activity (Fig. 1A and C). Because these regions essential to the
dominant-negative activity of Nmd2p include the principal
Upf3p-interacting domain (Fig. 1A), it is formally possible that
the dominant-negative effect is attributable to the saturation of
functional Upf3p with nonfunctional Nmd2p. However, two
observations indicate that the dominant-negative fragment of
Nmd2p must target a factor other than Upf3p: (i) overexpres-
sion of Upf3p does not reverse the dominant inhibition (Fig.
5), and (ii) there is no correlation between the efficiency with
which Nmd2p fragments bind Upf3p in the two-hybrid assay
and the extent of dominant-negative inhibition by the same
fragments (Fig. 1).
The simplest explanation for these observations is that both
the principal Upf3p-interacting domain (residues 564 to 771)
and the region from residue 772 to 816 may contribute to the
binding of yet another factor and that overexpression of the
dominant-negative Nmd2p fragment leads to titration of only
that unidentified factor. Alternative explanations include the
possibility that the region from residue 772 to 816 is part of the
binding site for a novel factor and that both this factor and
Upf3p are simultaneously titrated by overexpression of domi-
nant-negative Nmd2p. A variation on the latter hypothesis
suggests that binding of the novel factor to Nmd2p may require
the presence of Upf3p. Clearly, further characterization of the
genes identified in the two-hybrid screen in which the nmd2
dominant-negative fragment was used as bait may help to elu-
cidate the mechanism in question.
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